Globally competitive facilities

OUR PRODUCTION FACILITIES

Standing among the best production facilities in Korea, our plants operate under the global standards and are fully equipped with state-of-the-art systems.

Osong plant is Korea’s top-rank pharmaceutical manufacturing facility where high-quality oral solid dosage forms and oncology injectables are manufactured.

ADDRESS 239, Osongsaengmyeong 2-ro, Mansu-ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28158, Republic of Korea
SITE AREA 146,013 m²
BUILDING AREA 25,184.5 m²
MANUFACTURING FACILITIES Oral Solid Dosage Forms, Cytotoxic Oncology Injectables, Automated Warehouse, QC/QA Building, etc.
PRIMARY PRODUCTS Oral solid dosage forms, oncology injectables

ORAL SOLID DOSAGE FORMS

Closed system for manufacturing high-quality products at various scales

  • 3 identical granulation lines with the capacity of 30/100/300 Kg
  • 2 billion tablets and 1 billion capsules per year

The production area for oral solid dosage forms is designed to minimize mix-up between different processes from warehousing to the final step. All products are manufactured in a completely sealed condition by using the BIN system in order to eliminate external and cross contamination. In addition, various-scaled production is possible with establishment of the 30/100/300kg granule lines. The modern production equipment of the Osong plant for production of high-quality tablets/capsules is being utilized as infrastructure for product development, clinical sample, and commercial product manufacturing. All facilities are operated under the automatic computerized predefined system meeting 21 CFR Part 11.

CYTOTOXIC ONCOLOGY INJECTABLES

Dedicated site for cytotoxic oncology products
Secure from external contamination by operating closed system

  • Building dedicated to the cytotoxic injectables
  • Closed Restricted Access Barrier System technology

The separate Cytotoxic injectables facility handles all of manufacturing processes including manufacturing, storage, packaging, and quality control. It has been designed to perfectly respond to the increasingly toughened global regulations. The Cytotoxic injectables facility is characterized by not only the separate water/HVAC system but also the state-of-the-art facilities including the prescription department featuring automatic CIP/SIP, the isolators for weighing, the aseptic transfer system, and the filling & capping machines adopting the cRABS(closed Restricted Access Barrier System) technology. All the processes are operated under a perfectly closed system to prevent from external contamination during the manufacturing of cytotoxic injectables and to ensure safe environment for workers..

Osong plant is Korea’s top-rank pharmaceutical manufacturing facility where high-quality oral solid dosage forms and oncology injectables are manufactured.

ADDRESS Deokpyeong-ro, Deokpyeong-ri, Majang-myeon, Icheon-si, Gyeonggi-do 17389, Republic of Korea
SITE AREA 169,377 m²
BUILDING AREA 13,670 m²
MANUFACTURING FACILITIE Production Building, Bulk Building, Quality Building, Research Building, Warehouse Building
MAJOR DOSAGE FORMS Biologics and antibiotics (vials, prefilled syringes)

INJECTIONS PRODUCTION BUILDING

Production of biomedicines and drug products under the current GMP regulations

The processes, including sterile process, are designed to produce biologics, drug products, and biomedicines that are in compliance with the latest GMP regulations, under thorough quality control, and this satisfies the requirements of regulatory authorities and exporting countries.

EPOKINE Bulk Production Building

Production of the bulk of biologics based on 30-year production technologies

Here, culture process is run based on Cellmate that the culture of animal cells is automated, and optimal sterile products are produced through purification and filtration following cell culture and harvest.

Virus Vaccine Bulk Production Building

Production of virus vaccine bulk under the latest GMP regulations

A separately isolated building is operated for virus production, and all processes are being performed in sterile facilities, such as cellular culture, infection, harvest, release, etc. Also, cold storage is operated to meet the storage conditions of manufactured products.

Daeso Plant produces fluids, Antibiotic FPP & API(Cepha) and general APIs for domestic and global supplies.

* API (Active Pharmaceutical Ingredient(s))
* FPP (Finished Pharmaceutical Product(s)) 

ADDRESS 20, Daesosandan-ro, Daepung-ri, Daeso-myeon, Eumseong-gun, Chungcheongbuk-do, Republic of Korea
SITE AREA 58,278 m²
BUILDING AREA 28,313 m²
MANUFACTURING FACILITIES IV Solutions Building, Cepha Drug Products Building, Cepha Ingredients Building, Oral APIs Building, Automatic Warehouse Building
MAJOR DOSAGE FORMS Fluids / Internal Solids / Cepha Injection APIs / General Oral APIs

IV SOLUTION BUILDING

Establishment of automation system of the current GMP leve,
conveyer system-based production

Basic solution, nutrient fluids, special fluids, premix fluids, and TPN(Total Parenteral Nutrition) are produced. Equipped with FFS(forming/filling/sealing) system where manufacturing/filling/sealing of bags are done one-stop, the factory takes the lead of domestic fluids business.
*TPN (Total Parenteral Nutrition)

ANTIBIOTICS(CEPHA) PRODUCTION BUILDING

Contract manufacturing antibiotic APIs and supplying to Japanese originators

As exclusive facilities for Cepha drug product, the building is equipped with blockade system to prevent β-lactam* from leakage, and it is being exported to a Japanese originators with recognition for its 20-year technology.

  • Banan Tab. (Cefpodoxime Proxetil)
  • Banan Dry Syrup (Cefpodoxime Proxetil)

* β-lactam: An antibiotic exercising antibacterial effects by inhibiting the cell wall from synthesis; Penicillin and cephalosporin are the most typical antibiotics of β-lactam antibiotics.

ANTIBIOTICS(CEPHA) API PRODUCTION BUILDING

API exports to Japanese originators

As exclusive facilities for Cepha, API, the building is equipped with blockade system to prevent β-lactam from leakage, as well as Restricted Access Barrier System(RABS). Also, the site was approved by PMDA(Pharmaceuticals and Medical Agency) in Japan, and API is exported to originators in Japan.

  • Sterile Cefotiam HCl
  • Sterile Cefmenoxime HCl
  • Cefozopran HCl

* * β-lactam: An antibiotic exercising antibacterial effects by inhibiting the cell wall from synthesis; Penicillin and cephalosporin are the most typical antibiotics of β-lactam antibiotics
*API (Active Pharmaceutical Ingredient(s)) : Raw materials for medicine production
*RABS : Restricted Access Barrier System

GENERAL APIS BUILDING

CMO of Japanese originators Export of antibiotic Cepha APIs

As exclusive manufacturing site for general APIs, the building has acquired facility certification from the Ministry of Food and Drug Safety (MFDS), and based on internal ingredient synthesis technology, high-purity APIs are being produced and supplied.

*API (Active Pharmaceutical Ingredient(s)) : Nguyên liệu sản xuất thuốc